Search Results

CERESPIR INCORPORATED announced the formation of an expanded Clinical Advisory Board to support Phase 2 clinical development of its lead compound itanapraced in Parkinson’s disease.

CERESPIR INCORPORATED, a pharmaceutical company engaged in the discovery and development of disease modifying therapeutics for the treatment of neurodegenerative diseases, announced today it has identified a possible heretofore unknown link between COVID-19 induced brain inflammation and Acute Respiratory Stress Syndrome (ARDS), the most common cause of death among infected patients.